A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 2, 2008, Pages 203-214

  Andrews, Peter ^a   Zhao, Xu ^a   Allen, Jeffrey ^a   Li, Fengmin ^a   Chang, Melissa ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; COX 2; Drug resistance; Nitric oxide; NSAIDs; p75NTR

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2; FLURBIPROFEN; IBUPROFEN; MULTIDRUG RESISTANCE PROTEIN 1; NCX 1102; NCX 2111; NCX 2131; NCX 4050; NEUROTROPHIN RECEPTOR; NITRIC OXIDE; PROTEIN P75; SMALL INTERFERING RNA; SULFONE; SULINDAC; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL GROWTH; CELL SURVIVAL; COLON CANCER; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MALE; NEUROBLASTOMA; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; STAINING; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; UPREGULATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DATA INTERPRETATION, STATISTICAL; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; RECEPTOR, NERVE GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 36349003399     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0462-3     Document Type: Article

References (72)

1. Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI (1992) Gastrointestinal damage associated with the use of non-steroidal anti-inflammatory drugs. N Engl J Med 327:749-754
2. Alshafie GA, Abou-Issa HM, Seibert K, Harris RE. (2000) Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep 7:1377-1381
3. Andrews J, Djakiew D, Krygier S, Andrews PM (2002) Superior effectiveness of ibuprofen compared with other NSAIDs for inhibition of human prostate cancer cell growth. Cancer Chemother Pharmacol 50:277-284
4. Baron JA (2003) Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog Exp Tumor Res 37:1-24
5. Basu GD, Pathangey LB, Tinder TL, Lagioia M, Gendler SJ, Mukherjee P (2004) Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res 2:632-642
6. Carini M, Aldini G, Orioli M, Piccoli A, Tocchetti P, Facino RM (2004) Chemiluminescence and LC-MS/MS analyses for the study of nitric oxide release and distribution following oral administration of nitroaspirin (NCX 4016) in healthy volunteers. J Pharm Biomed Anal 35:277-287
7. Chan TA, Morin PJ, Vogelstein B, Kinzler KW (1998) Mechanisms underlying nonsteroidal anti-inflammatory drug-mediated apoptosis. PNAS 95:681-689
8. Chao MV (1994) The p75 neurotrophin receptor. J Neurobiol 25:1373-1385
9. Chapman BS (1995) A region of the 75kD neurotrophin receptor homologous to the death domains of TNFR-1 and Fas. FEBS Lett 374:216-220
10. Chiroli V, Benedini F, Ongini E, Del Soldato P (2003) Nitric oxide-donating non-steroidal anti-inflammatory drugs: the case of nitroderivatives of aspirin. Eur J Med Chem 38:441-446
11. Cullen KJ, Newkirk KA, Schumaker LM, Aldosari N, Rone JD, Haddad BR (2003) Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors. Cancer Res 63:8097-8102
12. Davies NM, McLachlan AJ, Day RO, William KM (2000) Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclooxygenase-2 inhibitor. Clin Pharmacokinet 38:225
13. Diperna CA, Bart RD, Sievers EM, Ma Y, Starnes VA, Bremner RM (2003) Cyclooxygenase-2 inhibition decreases primary and metastatic tumor burden in a murine model of orthotopic lung adenocarcinoma. J Thorac Cardiovasc Surg 126:1129-1133
14. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE (1998) Cyclooxygenase in biology and disease. FASEB J 12:1063-1073
15. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183-1188
16. George JA, Chen T, Taylor CC (2005) Src tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but coorperatively to restore pacilitaxel sensitivity to paclitaxel-resistant ovarian cancer cells. Cancer Res 65:10381-10388
17. Goluboff ET, Shabsigh A, Saidi JA, Weinstein IB, Mitra N, Heitjan D, Piazza GA, Pamukcu R, Buttyan R, Olsson CA (1999) Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology 53:440-445
18. Grubbs CJ, Lubet RA, Koki AT, Leahy KM, Masferrer JL, Steele VE, Kelloff GJ, Hill DL, Seibert K (2000) Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)- nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 15:5599-5602
19. Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L, Shiff SI, Rigas B (1996) Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin- independent pathway. Biochem Pharmacol 52:237-245
20. Harris RE, Alshafie GA, Abou-Issa H, Seibert K (2000) Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 60:2101-2103
21. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS (2000) The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275:11397-11400
22. Huber LJ, Chao MV (1995) Mesenchymal and neuronal cell expression of the p75 neurotrophin receptor gene occur by different mechanisms. Develop Biol 167:227-238
23. Huguenin S, Vacherot F, Kheuang L, Fleury-Feith J, Jaurand MC, Bolla M, Riffaud JP, Chopin DK (2004) Antiproliferative effect of nitrosulindac (NCX 1102), a new nitric oxide-donating non-steroidal anti-inflammatory drug, on human bladder carcinoma cell lines. Mol Cancer Ther 3:291-298
24. Ito H, Nomoto H, Furukawa S (2003) Growth arrest of PC12 cells by nerve growth factor is dependent on the phosphatidylinositol 3-kinase/Akt pathway via p75 neurotrophin receptor. J Neurosci Res 72:211-217
25. Kashfi K, Ryan Y, Qiao LL, Williams JL, Chen J, Del Soldato P, Traganos F, Rigas B, Ryann Y (2002) Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect. J Pharmacol Exp Ther 303:1273-1282
26. ntr tumor suppressor protein. Cancer Res 64:6207-6213
27. Konturek PC, Nikiforuk A, Kania J, Raithel M, Hahn EG, Muhldorfer S 2004 Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and over expression of COX-2, PPARgamma and growth factors. Dig Dis Sci 49:1075-1083
28. NTR suppresses growth and nerve growth factor-mediated metastasis of human prostate cancer cells. Int J Cancer 98:1-7
29. Latil A, Bieche I, Vidaud D, Lidereau R, Berthon P, Cusenot O, Vidaud M (2001) Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 61:1919-1926
30. Lilley M, Ruckle H, Quiggle D, Gutierrez I, Murray ED, Gibson K, Leipold D, Wechter WJ, Loughman B (2001) Multi-dose phase I-II trial of E-7869 in prostate cancer patients: Safety and time to PSA progression (TPSAP). Proc of AACR 42:142
31. Lim JT, Piazza GA, Han EK, Delohery TM, Li H, Finn TS, Buttyan R, Yamamoto H, Sperl GJ, Brendel K, Gross PH, Pamukcu R, Weinstein IB (1999) Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem Pharmacol 58:1097-1015
32. Lockwood GF, Albert KS, Gillespie WR, Bole GG, Harkcom TM, Szpunar GJ, Wagner JG (1983) Pharmacokinetics of ibuprofen in man. I. Free and total area/dose relationships. Clin Pharmacol Ther 34:97-103
33. McCracken JD, Wechter WJ, Lui Y, Chase RL, Kantoci D, Murray ED, Quiggle DD, Mineyama Y (1996) Antiproliferative effects of the enantiomers of flurbiprofen. J Clin Pharmacol 36:540-545
34. Mahmoud NN, Boolbol SK, Dannenberg AJ, Mestre JR, Bilinski RT, Martucci C, Newmark HL, Chadburn A, Bertagnolli MM (1998) The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogenesis 19:87-91
35. Malkinson AM, Koski KM, Dwyer-Nield LD, Rice PL, Rioux N, Castonguay A, Ahnen DJ, Thompson H, Pamukcu R, Piazza GA (1998) Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung tumor formation by FGN-1 (sulindac sulfone) Carcinogenesis 19:1353-1356
36. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K (2000) Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60:1306-1311
37. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival. J Immunol Methods 65:560-567
38. Murray ED, Quiggle D, Gibson K, Leipold D, Loughman B, Wechter W (2000) Phase I single-dose pharmacokinetics and lack of bioinversion of E-7869 (R-flurbiprofen). Clin Pharma Ther 67:103
39. Narisawa T, Hermanek P, Habs M, Schmahl D (1984) Reduction of carcinogenicity of N-nitrosomethylurea by indomethacin and failure of resuming effect of prostaglandin E2 (PGE2) against indomethacin. J Cancer Res Clin Oncol 108:239-242
40. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM (1996) Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87:803-809
41. Park C, Kim GY, Kim GD, Choi BT, Park YM, Choi YH (2006) Induction of G2/M arrest and inhibition of cyclooxygenase-2 activity by curcumin in human bladder cancer T24 cells. Oncol Rep 15:1225-1231
42. Piazza GA, Alberts DS, Hixson LJ, Paranka NS, Li H, Finn T, Bogert C, Guillen JM, Brendel K, Gross PH, Sperl G, Ritchie J, Burt RW, Ellsworth L, Ahnen DJ, Pamukcu R (1997) Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 57:2909-2915
43. Piazza GA, Rahm AK, Finn TS, Fryer BH, Li H, Stoumen AL, Pamukcu R, Ahnen DJ (1997) Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res 57:2452-2459
44. Piazza GA, Thompson WJ, Pamukcu R, Alila HW, Whitehead CM, Liu L, Fetter JR, Gresh WE Jr, Klein-Szanto AJ, Farnell DR, Eto I, Grubbs CJ (2001) Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Cancer Res 61:3961-3968
45. Quiggle DD, Lilly M, Murray ED, Gibson KM, Leipold DD, Gutierrez I, Loughman BE, Wechter WJ (2000) PK guided multi-dose, tolerance and safety of E-7869 in prostate cancer patients. Proc Am Assoc Cancer Res 41:609
46. Rath GD (1992) Bladder cancer, 1992. Postgrad Med 92:105-124
47. Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S, Seibert K, Rao CV (2000) Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 60:293-297
48. Reddy BS, Kawamori T, Lubet RA, Steele VE, Kelloff GJ, Rao CV (1999) Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process. Cancer Res 59:3387-3391
49. Roberts RO, Jacbson DJ, Girman CJ, Rhodes T, Lieber MM, Jacobsen SJ (2002) A population-based study of daily nonsteroidal anti-inflammation drug use and prostate cancer. Mayo Clin Proc 77:219-225
50. Ruegg C, Zaric J, Stupp R (2003) Non steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-cancer therapeutics: hypes, hopes and reality. Ann Med 35:476-487
51. Sabichi AL, Lippman SM (2004) COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary cancer. Semin Oncol 31:36-44
52. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T (1995) Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 55:3785-3789
53. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN (1998) Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 58:362-366
54. Smith ML, Hawcroft G, Hull MA (2000) The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Eu J Cancer 36:664-674
55. Song MS, Posse de Chaves EI (2003) Inhibition of rat sympathetic neuron apoptosis by ceramide. Role of p75NTR in ceramide generation. Neuropharmacology 45:1130-1150
56. Stewart DJ (1984) Novel modes of chemotherapy administration. Prog Exp Tumor Res 28:32-50
57. Taketo MM (1998) Cyclooxygenase-2 inhibitors in tumorigenesis. (Part II) J Natl Cancer Inst 90:1609-1620
58. Tabassum A, Khwaja F, Djakiew D (2003) The p75(NTR) tumor suppressor induces caspase-mediated apoptosis in bladder tumor cells. Int J Cancer 105:47-52
59. Tegeder I, Pfeilschifter J, Geisslinger G (2001) Cyclooxygenase- independent actions of cyclooxygenase, inhibitors. FASEB J 15:2057-2072
60. Thompson HJ, Jiang C, Lu J, Mehta RG, Piazza GA, Paranka NS, Pamukcu R, Ahnen DJ (1997) Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res 15:267-271
61. Tsujii M, Kawano S, Tsuiji S, Sawaoka H, Hori M, DuBois RN (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705-716
62. Vainio H (2001) Is COX-2 inhibition a panacea for cancer prevention? Int J Cancer 1:613-614
63. Wechter WJ, Kantoci D, Murray ED Jr, Quiggle DD, Leipold DD, Gibson KM, McCracken JD (1997) R-flurbiprofen chemoprevention and treatment of intestinal adenomas in the APC(Min)/+ mouse model: implications for prophylaxis and treatment of colon cancer. Cancer Res 57:4316-4324
64. Wechter WJ, Leipold DD, Murray ED, Quiggle D, McCracken JD, Barrios RS, Greenberg NM (2000) E-7869 (R-Flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res 60:2203-2208
65. Wilgus TA, Koki AT, Zweifel BS, Rubal PA, Oberyszyn TM (2003) Chemotherapeutic efficacy of topical celecoxib in a murine model of ultraviolet light B-induced skin cancer. Mol Carcinog 38:33-39
66. Witta SE, Gustafson DL, Pierson AS, Menter A, Holden SN, Basche M, Persky M, O'Bryant CL, Zeng C, Baron A, Long ME, Gibbs A, Kelly K, Bunn PA Jr, Chan DC, Pallansch P, Eckhardt SG (2004) A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors. Clin Cancer Res 1:7229-7237
67. Xu XC (2002) COX-2 inhibitors in cancer treatment and prevention, a recent development. Anticancer Drugs 13:127-137
68. Yeh RK, Chen J, Williams JL, Baluch M, Hundley TR, Rosenbaum RE, Kalala S, Traganos F, Benardini F, del Soldato P, Kashfi K, Rigas B (2004) NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property? Biochem Pharmacol 67:2197-2205
69. Yoon SO, Casaccia-Bonnefil P, Carter B, Chao MV (1998) Competitive signaling between TrkA and p75 nerve growth factor receptors determines cell survival. J Neurosci 18:3273-3281
70. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM, Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM (2004) Cyclooxygenases in cancer: progress and perspective. Cancer Lett 215:1-20
71. Zhang X, Morham SG, Langenbach R, Young DA (1999) Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med 190:451-459
72. Zweifel BS, Davis TW, Ornberg RL, Masferrer JL (2002) Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors. Cancer Res 62(22):6706-6711